ENANTA PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $331.92M
- P/E (TTM)
- –
- Dividend yield
- –
About Enanta Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule oral drug candidates for virology and immunology indications. Within virology, the company discovered glecaprevir, an antiviral protease inhibitor co-formulated in AbbVie's combination treatments for hepatitis C virus, and develops clinical-stage candidates targeting respiratory syncytial virus, COVID-19, and hepatitis B virus. In immunology, Enanta targets biological mechanisms such as KIT and STAT6 to design therapies for type 2 inflammatory diseases, focusing proof-of-concept efforts on conditions such as chronic spontaneous urticaria and atopic dermatitis. The company engages in collaborative partnerships and utilizes contract research organizations for development and commercialization.
The company maintains its principal executive offices in Watertown, Massachusetts. Enanta conducts preclinical studies and clinical trials targeting domestic and global patient populations affected by serious viral infections and chronic inflammatory conditions. Development operations are performed through contract research facilities and collaborative relationships.
Summary of the business section of Enanta Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ENANTA PHARMACEUTICALS INC
- Headquarters
- Watertown, MA
- Address
- 4 Kingsbury Avenue 02472
- Phone
- (617) 607-0800
- Employees
- 120, Sep 30, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- September 30
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ENTA
- Exchange
- Nasdaq
- IPO date
- Mar 21, 2013
- Shares outstanding
- 29M, Aug 7, 2026
- Public float
- $110.59M, Mar 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1177648
- CUSIP
- 29251M106
- ISIN
- US29251M1062
- LEI
- 529900SSN4DODDQSN594
- EIN
- 04-3205099
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jay R. Luly | President and CEO, Director | 871,871 |
| Scott T. Rottinghaus | Chief Medical Officer | 23,787 |
| Yat Sun Or | Chief Scientific Officer | 374,854 |
| Brendan Luu | Chief Business Officer | 44,891 |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 32,195 |
| Matthew Paul Kowalsky | Chief Legal Officer | 3,591 |
| Harry R. Trout III | See Remarks | 16,348 |
| Kathleen S. Capps | See Remarks | 8,377 |
| Paul J. Mellett | Chief Fin. & Admin Officer | 99,210 |
| Lesley Russell | Director | – |
| Yujiro S. Hata | Director | – |
| Kristine Peterson | Director | – |
| Mark G. Foletta | Director | – |
| Bruce L. A. Carter | Director | 0 |
| Terry Vance | Director | 5,800 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jay R. Luly, Ph.D | $2.77M | $3.60M | $1.32M | $23 | – |
| FY2024 Jay R. Luly, Ph.D | $2.70M | $2.19M | $1.27M | $20 | – |
| FY2023 Jay R. Luly, Ph.D | $7.86M | -$2.47M | $2.81M | $22 | – |
| FY2022 Jay R. Luly, Ph.D | $5.29M | $6.33M | $2.11M | $124 | $119 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of September 30, 2025, we had 120 full-time employees, 61 of whom hold Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 10, 2022 | Late filing | Notification of late filing |
| Mar 21, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 18, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |